

REPORT DOCUMENTATION PAGE			Form Approved OMB NO. 0704-0188		
<p>The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA, 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.</p> <p>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</p>					
1. REPORT DATE (DD-MM-YYYY) 22-07-2013		2. REPORT TYPE Final Report		3. DATES COVERED (From - To) 1-Sep-2012 - 31-May-2013	
4. TITLE AND SUBTITLE Antimicrobial peptide-PNA conjugates selectively targeting bacterial genes			5a. CONTRACT NUMBER W911NF-12-1-0408		
			5b. GRANT NUMBER		
			5c. PROGRAM ELEMENT NUMBER 611102		
6. AUTHORS Kallenbach, Neville R.			5d. PROJECT NUMBER		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAMES AND ADDRESSES New York University Office of Sponsored Programs 15 Washington Place, 1-H New York, NY 10003 -			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Research Office P.O. Box 12211 Research Triangle Park, NC 27709-2211			10. SPONSOR/MONITOR'S ACRONYM(S) ARO		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S) 62426-LS-II.1		
12. DISTRIBUTION AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision, unless so designated by other documentation.					
14. ABSTRACT As summarized in ARO Topic A09A-T004, resistance to antibiotics in current use continues to spread, while the pipeline of approved new antibiotics is shrinking. Antibiotic therapy today is a crude and increasingly ineffective weapon against infection. Current broad spectrum antibiotics notoriously stimulate the spread of resistance, and also open the way to secondary infections by MRSA and other pathogens. We offer here a solution that avoids stimulating resistance as well as collateral damage to the natural biome: a target selective antimicrobial therapy. As					
15. SUBJECT TERMS final report, STIR, new narrow spectrum anti-infectives					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	15. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON Neville Kallenbach
a. REPORT UU	b. ABSTRACT UU	c. THIS PAGE UU			19b. TELEPHONE NUMBER 212-998-8757

## Report Title

Antimicrobial peptide-PNA conjugates selectively targeting bacterial genes

### ABSTRACT

As summarized in ARO Topic A09A-T004, resistance to antibiotics in current use continues to spread, while the pipeline of approved new antibiotics is shrinking. Antibiotic therapy today is a crude and increasingly ineffective weapon against infection. Current broad spectrum antibiotics notoriously stimulate the spread of resistance, and also open the way to secondary infections by MRSA and other pathogens. We offer here a solution that avoids stimulating resistance as well as collateral damage to the natural biome: a target selective antimicrobial therapy. As a proof-of-concept project, this proposal seeks to explore the possibility that non-covalently linked combinations of peptide mimetics and peptide nucleic acids (PNA's) provide a basis for a strain-selective antibacterial therapy. Initial publications suggest that conjugates of cell penetrating peptides and PNA's can overcome the barrier in transporting the PNA's into cells. The strategy is to use (RW)4D and (RW)3, both designed in our lab, to guide a PNA sequence (conjugated or not) to the appropriate target RNA and thereby silence its expression. In initial testing, we used PNA sequences designed to inhibit growth of E. coli and MRSA cells, already reported in literature previously, but using our RW motif. Our preliminary results with this experiment are positive!

---

**Enter List of papers submitted or published that acknowledge ARO support from the start of the project to the date of this printing. List the papers, including journal references, in the following categories:**

**(a) Papers published in peer-reviewed journals (N/A for none)**

Received

Paper

**TOTAL:**

**Number of Papers published in peer-reviewed journals:**

---

**(b) Papers published in non-peer-reviewed journals (N/A for none)**

Received

Paper

**TOTAL:**

**Number of Papers published in non peer-reviewed journals:**

---

**(c) Presentations**

**Number of Presentations:** 0.00

**Non Peer-Reviewed Conference Proceeding publications (other than abstracts):**

<u>Received</u>	<u>Paper</u>
-----------------	--------------

**TOTAL:**

**Number of Non Peer-Reviewed Conference Proceeding publications (other than abstracts):**

**Peer-Reviewed Conference Proceeding publications (other than abstracts):**

<u>Received</u>	<u>Paper</u>
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100

**TOTAL:**

**Number of Peer-Reviewed Conference Proceeding publications (other than abstracts):**

### (d) Manuscripts

<u>Received</u>	<u>Paper</u>
-----------------	--------------

**TOTAL:**

**Number of Manuscripts:**

## Books

<u>Received</u>	<u>Paper</u>
-----------------	--------------

**TOTAL:**

## Patents Submitted

Provisional filing via NYU IP department in progress

## Patents Awarded

## Awards

## Graduate Students

<u>NAME</u>	<u>PERCENT SUPPORTED</u>
-------------	--------------------------

**FTE Equivalent:**

**Total Number:**

## Names of Post Doctorates

<u>NAME</u>	<u>PERCENT SUPPORTED</u>
-------------	--------------------------

Totsingan, Filbert	0.50
--------------------	------

Liu, Zhigang	0.50
--------------	------

<b>FTE Equivalent:</b>	<b>1.00</b>
------------------------	-------------

<b>Total Number:</b>	<b>2</b>
----------------------	----------

## Names of Faculty Supported

<u>NAME</u>	<u>PERCENT SUPPORTED</u>
-------------	--------------------------

**FTE Equivalent:**

**Total Number:**

## Names of Under Graduate students supported

<u>NAME</u>	<u>PERCENT SUPPORTED</u>	Discipline
-------------	--------------------------	------------

Buitrago, Carlos	0.00	Biosciences
------------------	------	-------------

Mohamed, Mohamed A.	0.00	Chemistry
---------------------	------	-----------

<b>FTE Equivalent:</b>	<b>0.00</b>
------------------------	-------------

<b>Total Number:</b>	<b>2</b>
----------------------	----------

### Student Metrics

This section only applies to graduating undergraduates supported by this agreement in this reporting period

The number of undergraduates funded by this agreement who graduated during this period: ..... 0.00

The number of undergraduates funded by this agreement who graduated during this period with a degree in science, mathematics, engineering, or technology fields:..... 0.00

The number of undergraduates funded by your agreement who graduated during this period and will continue to pursue a graduate or Ph.D. degree in science, mathematics, engineering, or technology fields:..... 0.00

Number of graduating undergraduates who achieved a 3.5 GPA to 4.0 (4.0 max scale): ..... 0.00

Number of graduating undergraduates funded by a DoD funded Center of Excellence grant for Education, Research and Engineering:..... 0.00

The number of undergraduates funded by your agreement who graduated during this period and intend to work for the Department of Defense ..... 0.00

The number of undergraduates funded by your agreement who graduated during this period and will receive scholarships or fellowships for further studies in science, mathematics, engineering or technology fields: ..... 0.00

### Names of Personnel receiving masters degrees

NAME

Total Number:

### Names of personnel receiving PhDs

NAME

Kallenbach, Neville R.

Total Number:

1

### Names of other research staff

NAME

PERCENT SUPPORTED

FTE Equivalent:

Total Number:

### Sub Contractors (DD882)

### Inventions (DD882)

## Scientific Progress

### Antimicrobial peptide-PNA conjugates selectively targeting bacterial genes

#### Abstract

As summarized in ARO Topic A09A-T004, resistance to antibiotics in current use continues to spread, while the pipeline of approved new antibiotics is shrinking. Multidrug resistance (MDR) among pathogens is a persistent problem, for civilians as well as military personnel wounded in the field, in hospitals where wounded personnel associate with other patients, and in community venues. Antibiotic therapy today is a crude and increasingly ineffective weapon against infection. Current broad spectrum antibiotics also open the way to secondary infections by MRSA and other pathogens that threaten patient life and health, including *C. difficile*. Thus, antibacterial strategies that provide timely and effective therapeutic countermeasures are urgently required for possible outbreaks of MRSA or other MDR infections.

As a proof-of-concept project, this proposal seeks to explore the possibility that non-covalently linked combinations of peptide mimetics and peptide nucleic acids (PNA's) provide a basis for a strain-selective antibacterial therapy. Initial publications suggest that conjugates of cell penetrating peptides and PNA's can overcome the barrier in transporting the PNA's into cells. The strategy is to use (RW)4D, a peptidodendrimer from our lab and (RW)3, a linear peptide, to guide a PNA sequence (conjugated or not) to the appropriate target RNA and thereby silence its expression. In initial testing, we used PNA sequences designed to inhibit growth of *E. coli* and MRSA cells, already reported by Nielsen's group and Luo's group (Bai, 2012), respectively, but using our RW motif. Our preliminary results with this experiment are positive!

We apologize for lateness of this report, but our laboratory has just been moved from 1166 Waverly to smaller space in 866 Waverly, with facilities up to now.

#### 1. Tasks

##### 1.1. Synthesize antisense PNA sequences, RW peptides and conjugates

##### 1.2. Microdilution assay of MRSA and *E. coli* cell growth in the presence of single PNAs, peptide, and PNA-peptide conjugates

##### 1.3. Synergistic effect of PNA and RW-peptide mixture against bacterial growth

#### 2. Results and Analysis

##### 2.1. Synthesize antisense PNA and PNA-peptide conjugate

Antisense antibacterials are short (about 10 bases) synthetic DNA analogs that inhibit essential gene expression at the mRNA level in a sequence-specific manner (Rasmussen, 2007). The neutral and flexible PNA backbone offers important advantages in hybridization with a complementary nucleic acid: the  $T_m$  of complexes is higher than DNA-DNA for example, and less sensitive to ionic strength. Antisense inhibition by a PNA depends on the function of the targeted gene. Antisense inhibition of  $\beta$ -galactosidase shut down  $\beta$ -galactosidase synthesis with a well-calibrated colorimetric assay in *E. coli* based on the X-gal blue-white color change, (Good, 2000). In the case of MRSA, RNA polymerase  $\sigma^{70}$  (encoded by gene *rpoD*) is a conserved prokaryotic factor essential for transcription initiation in exponentially growing MRSA, implying strong potential to achieve antisense inhibition (Paget, 2003).

Antisense oligomers, especially peptide nucleic acid (PNA) (Nielsen, 2010) possess favorable properties in light of antisense antibacterial application, including improved targeting specificity, binding affinity, biological stability and access to a variety of chemical modification. A major challenge for the application of PNA gene silencing technology to bacteria is the inefficient entry of PNAs into the targeted cell due to restrictions imposed by the bacterial membrane. Peptide (RXR)4XB and (KFF)3K, were previously reported as a potent permeabilizer against *E. coli* and MRSA cells (Mellbye, 2009). (RW)4D, a small dendrimeric AMP and (RW)3, a linear hexameric peptide, both designed in our lab, interact with wall polymers and cause penetration of the cell membrane at sub-lethal concentration (Liu, 2007).

Scheme 1. Synthesis of PNA-dendrimer conjugate. (a) (RW)4D-cysteine (b) Free PNA (C) PNA-(RW)4D conjugates.

MRSA RNA polymerase-*rpoD*-targeting antisense PNA (PNA 1) and *E. coli*  $\beta$ -galactosidase-*lacZ*-targeting antisense PNA (PNA 4) were synthesized by standard solid phase synthesis (SPPS) (Nielsen, 2010; Totsingan et al., 2010) (Table 1). Anti-*rpoD* PNA-(KFF)3K conjugates (PNA2), which showed bacteriocidal antisense effect against MRSA in previous study (Bai et al., 2012), was included as control. Anti-*rpoD* PNA-(RW)4D (PNA3) and Anti- *lacZ* PNA-(KFF)3K (PNA5) conjugates were

successfully synthesized by modifying the protocol reported in the literature (Good et al., 2000) (Nielsen, 2010) to accept self-penetrating peptides (Liu et al., 2007). All five PNAs were purified on RP-HPLC and confirmed with expected M.W. (Scheme 1, Figure 1, Table 1)

Fig. 1. ESI-MS of PNA1, PNA2 and PNA3. a) PNA1, H-TTTCTCGTCA-NH2, b) PNA2, Anti-rpoD PNA-(KFF)3K conjugates, c) PNA3, Anti-rpoD PNA-(RW)4D

Table 1: PNA sequences and the corresponding ESI-MS characterization

Designation	
PNA sequence	
#Bases	
Strain	ESI-MS data
(MW): Expected/found	
PNA1	
H-TTTCTCGTCA-NH2	
10	
MRSA	(2668.6): 1335.3/1335.3 (MH22+); 890.5/890.7 (MH33+); 668.2/668.4 (MH44+);534.7/535.0 (MH55+)
PNA2	
H-(KFF)3K-(β-ala)-TTTCTCGTCA-NH2	
10	
MRSA	(4135.4): 1034.9/1034.9 (MH44+); 828.1/828.5 (MH55+); 690.2/690.5 (MH66+);591.8/592.2 (MH77+)
PNA3	
(RW)4D-TTCTCGTCA-NH2	
10	
MRSA	(4493.8): 1124.5/1124.8 (MH44+); 899.8/900.1 (MH55+); 750.0/750.3 (MH66+);643.0/643.3 (MH77+)
PNA4	
H-TAGCTGTTTC-K-NH2	
10	
E coli K12	(2836.8): 946.6/946.3 (MH33+); 710.2/710.0 (MH44+); 568.4/568.2 (MH55+)
PNA5	
H-(KFF)3K-(□-Ahx)- TAGCTGTTTC-K-NH2	
10	
E coli K12	(4345.7): 870.1/870.2 (MH55+); 725.3/725.4 (MH66+); 621.8/621.9 (MH77+); 544.2/544.4 (MH88+)

2.2. Growth assays and susceptibility testing in the presence of constructs

The antibacterial activity of free PNAs, PNA-peptide conjugates and PNA/peptide mixtures were tested by following standard broth microdilution protocols recommended by the National Committee for Clinical Laboratory Standard (NCCLS). The growth inhibitory effect of PNA-Peptide conjugates were evaluated against MRSA and E coli K12 (Table 2). As expected, poor cellular uptake was confirmed with free PNAs (PNA1 and PNA4), which showed no growth inhibition effect at the highest concentrations tested (40 μM). Anti-rpoD PNA-(RW)4D (PNA3) and anti-rpoD PNA-(KFF)3K (PNA2) are potent and exhibit the same MIC values (15 μM) against MRSA. In the case of E.coli K12 strain. Despite the fact that the chosen sequence occurs in several copies in the chromosome and is not unique to the lac promoter, the PNA alone has no detectable activity below 40 μM. The sequence conjugated to (KFF)3K does, despite its selection to hybridize with lac mRNA.

Table 2: Summary of PNAs activity against MRSA and E coli K12.

Drug	Strains	MIC, μM
(RW)4D	MRSA	22±3.5
(KFF)3K	MRSA	>40
PNA1	MRSA	>40
PNA2	MRSA	15±2.3
PNA3	MRSA	15±1.9
PNA4	E coli K12	>40
PNA5	E coli K12	10 ±1.6

### 2.3. Synergistic effect of PNA and peptide mixture against bacterial growth

Relative to antisense PNA alone, mixture of various PNAs with RW-peptide showed 3-4 time increased growth inhibitory effects against MRSA and *E. coli*. and are even more potent than the corresponding RW-peptide (Figure 2 and Figure 3). The results demonstrate that RW-peptide and PNAs may act in a synergistic way.

Fig. 2. Antimicrobial activity against MRSA of Anti-rpoD PNA (PNA1), Anti-rpoD PNA-(RW)4D (PNA3) and PNA1/(RW)4D mixtures. Preliminary results showing active synergy between membrane penetrating (RW)4D peptide and decameric anti-rpoD PNA sequences in MRSA.

Fig. 3. Antimicrobial activity against *E. coli* K12 of Anti-lacZ PNA (PNA4) and PNA4/(RW)3 mixtures. Preliminary results showing active synergy between membrane penetrating RW peptide and a decameric PNA sequence present in multiple copies in *E. coli* K12.

The linear antimicrobial peptide (RW)3 is active, albeit only moderately so. An equimolar mix of (RW)3 and the PNA shows about two fold increase in activity. This implies that covalent conjugation may not ensure the best balance between the components. Based on the results, we believe we need to further optimize the ratios of the peptide and PNA to compare these to the conjugated chains. It is not clear that 1:1 ratios are close to the optimum.

### 3. Conclusions

The results so far confirm our hypothesis that conjugation of a cationic antimicrobial agent to a PNA might not offer the best approach for designing a target selective anti-infective. Instead we will monitor various ratios of the PNA vs AMP in order to find the optimum penetration/inactivation ratio.

3.1. (RW)4D and (RW)3 peptides conjugated to 10-mer PNAs (Anti-rpoD PNA and anti-LacZ PNA) have been successfully synthesized with expected M.W.

3.2. PNA conjugates show micromolar-range growth inhibitory effects against MRSA and *E. coli* in a concentration-dependent manner. PNA/peptide mixtures show increased growth inhibitory effects against MRSA and *E. coli*.

3.3. Combination of two agents, one that breaches the wall and membrane, the other that targets gene expression in a pathogen, offers an approach to a narrow spectrum anti-infective therapy that merits detailed investigation.

### 4. References

1. Bai, H., Sang, G., You, Y., Xue, X., Zhou, Y., Hou, Z., Meng, J., and Luo, X. Targeting RNA polymerase primary  $\sigma 70$  as a therapeutic strategy against methicillin-resistant *Staphylococcus aureus* by antisense peptide nucleic acid. *PLoS One*. 2012; 7(1):e29886.
2. Good, L., Sandberg, R., Larsson, O., Nielsen, P.E., and Wahlestedt, C. (2000). Antisense PNA effects in *Escherichia coli* are limited by the outer-membrane LPS layer. *Microbiology* 146 ( Pt 10), 2665-2670.
3. Liu, Z., Deshazer, H., Rice, A.J., Chen, K., Zhou, C., and Kallenbach, N.R. (2007). Tuning the membrane selectivity of antimicrobial peptides by using multivalent design. *ChemBiochem* 8, 2063-2065.
4. Mellbye, B.L., Puckett, S.E., Tilley, L.D., Iversen, P.L., and Geller, B.L. (2009) Variations in amino acid composition of antisense peptide-phosphorodiamidate morpholino oligomer affect potency against *Escherichia coli* in vitro and in vivo. *Antimicrob Agents Chemother* 53: 525–530.
5. National Committee for Clinical Laboratory Standard (NCCLS 2004).
6. Nielsen, P.E. (2010). Peptide nucleic acids (PNA) in chemical biology and drug discovery. *Chemistry & biodiversity* 7, 786-804.
7. Paget, M.S. and Helmann, J.D. (2003) The sigma70 family of sigma factors. *Genome Biol* 4: 203.
8. Rasmussen, R.V., Fowler, V.G., Jr., Skov, R., and Bruun, N.E. (2011) Future challenges and treatment of *Staphylococcus aureus* bacteremia with emphasis on MRSA. *Future Microbiol* 6: 43–56.
9. Totsingan, F., Jain, V., Bracken, C., Kallenbach, N.R., and Green, M. (2010). Conformational Heterogeneity in PNA:PNA Duplexes. *Macromolecules* 43, 2692-2703.

### Technology Transfer